The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.
Rusfertide effectively maintains hematocrit control and reduces phlebotomy need in PV patients, as shown in the VERIFY study over 52 weeks. The therapy, a hepcidin mimetic peptide, regulates iron ...
New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.
Cardiologists and pharmacy leaders explained how team-based clinics and standardized paperwork are speeding obstructive HCM ...
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small ...
CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic ...
An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.
Nearly 90% of patients in the MINT trial tapered prednisone to 5 mg/day or less, with no significant safety concerns seen to ...
Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.
Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, ...
Infectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer ...
Florin Draica of Shionogi explains the 72-hour PEP window for ensitrelvir, breakthrough infection data, and which patients to ...